Evidence map›Paper›PMID 42825054›Full record

ArticleRegenerative therapy2026

Pilot study of Wilms tumor 1-targeted human platelet lysate-induced antigen-presenting cells in advanced solid cancer patients.

Misa Togi, Terutsugu Koya, Kenichi Yoshida, Haruhiko Kawaguchi, Tamaki Takano, Sohsuke Yamada, Tsung-Jang Yeh, Yi-Chang Liu, Haruo Sugiyama, Shigeo Koido and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Misa TogiDepartment of Regenerative Medicine, Kanazawa Medical University, Uchinada, Kahoku, 920-0293, Japan.
Terutsugu KoyaDepartment of Regenerative Medicine, Kanazawa Medical University, Uchinada, Kahoku, 920-0293, Japan.
Kenichi YoshidaCenter for Regenerative Medicine, Kanazawa Medical University Hospital, Uchinada, Kahoku, 920-0293, Japan.
Haruhiko KawaguchiCenter for Regenerative Medicine, Kanazawa Medical University Hospital, Uchinada, Kahoku, 920-0293, Japan.
Tamaki TakanoDepartment of Cardiovascular Surgery, Kanazawa Medical University, Uchinada, Kahoku, 920-0293, Japan.
Sohsuke YamadaDepartment of Pathology and Laboratory Medicine, Kanazawa Medical University, Uchinada, Kahoku, 920-0293, Japan.
Tsung-Jang YehDivision of Hematology and Oncology, Kaohsiung Medical University Hospital, Kaohsiung City, 80756, Taiwan.
Yi-Chang LiuDivision of Hematology and Oncology, Kaohsiung Medical University Hospital, Kaohsiung City, 80756, Taiwan.
Haruo SugiyamaDepartment of Cancer Immunology, Graduate School of Medicine, Osaka University, Suita, 565-0871, Japan.
Shigeo KoidoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Kashiwa, 277-8567, Japan.
Shigetaka ShimodairaDepartment of Regenerative Medicine, Kanazawa Medical University, Uchinada, Kahoku, 920-0293, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: For the wide implementation of dendritic cell-based cancer immunotherapy, a clinical phase I study was conducted to explore its safety and tolerability using Wilms' tumor 1 (WT1) antigen-targeted human platelet lysate-induced antigen-presenting cells (WT1-HPL-APCs), developed by our team, in patients with advanced solid cancers. Methods: WT1-HPL-APCs were manufactured from apheresed peripheral blood mononuclear cells administered at 4 × 10 Results: The adverse events associated with WT1-HPL-APC vaccination included fever, erythema at the injection site, arthralgia, and chills, all of which were lower than grade 2 in two patients who completed three sessions. The WT1 expression levels and infiltration of CD4 Conclusions: As this pilot study included only three patients with different cancer types, evidence supporting the effectiveness or functionality of WT1-HPL-APCs remains limited. WT1-HPL-APC vaccination was tolerable among patients with advanced solid cancers. Our findings suggest that the immunoinducibility of WT1-HPL-APC vary across individuals and that the preexisting immunosuppressive environment could limit WT1-CTL induction. Future studies are warranted to determine whether WT1-HPL-APC vaccination can improve the patient's immunosuppressive environment and induce WT1-CTLs in combination with optimized chemotherapy or adjuvant therapy in large-scale clinical trials involving multiple doses. Clinical trial registration number: jRCTc040200005.

Indexed as

Antigen-presenting cellsCancerCell therapyHuman platelet lysateMonocytic myeloid-derived suppressor cellsWilms' tumor 1

Identifiers

PMID42825054
PMCPMC13628676

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.